SideMenu

In the News

AAM Comments on Department of Labor PBM Transparency and Disclosure Rule
October 30, 2026
FDA Building
AAM and Biosimilars Council Comment on GDUFA and BsUFA User Fee Negotiations and Reauthorization
September 25, 2026
U.S. Generic & Biosimilar Medicines Save $496B in Just 1 Year
September 10, 2026
Amneal Announces U.S. Expansion of End-to-End Biosimilars Development With Acquisition of Kashiv BioSciences
August 21, 2026
The Biosimilars Council and AAM Applaud Senate Markup and Committee Passage of the Expedited Access to Biosimilars Act
July 23, 2026
US Capitol in Washington DC
The Biosimilars Council and AAM Laud House Markup of Expedited Access to Biosimilars Act and Biosimilars Red Tape Elimination Act
July 21, 2026

Filter by Keyword

Filter by Audience

Filter by Category

Filter by Keyword

Filter by Issue

Filter by Category